{"transactions":[{"id":677463,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-24T21:11:12.000Z","date":"2026-08-21","kind":"sale","planned":true,"acquired":false,"shares":298853,"price":6.5126,"value":1946310.0478,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.37 to $6.75 per share. Upon request by the SEC, the Issuer or a stockholder of the Issuer, complete information regarding the number of shares sold at each price within the range will be provided."}],"balance_after":411976,"source":{"system":"sec-edgar","filing":"0001079973-26-001175","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000107997326001175/ownership.xml","form_type":"4"}},{"id":701480,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-29T22:49:15.000Z","date":"2026-07-27","kind":"grant","planned":false,"acquired":true,"shares":27108,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents grant of restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of the Issuer's common stock upon settlement. The RSUs vest in full on the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on the vesting date."}],"balance_after":710829,"source":{"system":"sec-edgar","filing":"0001079973-26-000983","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000107997326000983/ownership.xml","form_type":"4"}},{"id":967646,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-16T21:30:05.000Z","date":"2025-12-15","kind":"sale","planned":false,"acquired":false,"shares":13333,"price":3.7719,"value":50290.7427,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person used the proceeds of this sale to cover tax liabilities arising from the vesting of an RSU award on November 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Price of $3.771921 was the volume weighted average selling price of all sales by the reporting person on December 15, 2025 within a one-dollar range. Actual prices ranged from $3.770 to $3.785. The reporting person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price."}],"balance_after":683721,"source":{"system":"sec-edgar","filing":"0001079973-25-001861","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000107997325001861/ownership.xml","form_type":"4"}},{"id":990196,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-24T22:20:23.000Z","date":"2025-11-20","kind":"grant","planned":false,"acquired":true,"shares":32407,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents restricted stock units that were fully vested upon grant."}],"balance_after":697054,"source":{"system":"sec-edgar","filing":"0001553350-25-000143","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000155335025000143/ownership.xml","form_type":"4"}},{"id":990195,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-24T22:20:23.000Z","date":"2025-11-20","kind":"grant","planned":false,"acquired":true,"shares":41667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest in full on Issuer's 2026 annual stockholder meeting date, subject to continued service with the Issuer through such vesting date."}],"balance_after":664647,"source":{"system":"sec-edgar","filing":"0001553350-25-000143","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000155335025000143/ownership.xml","form_type":"4"}},{"id":1059309,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2025-08-21T19:13:31.000Z","date":"2025-08-19","kind":"sale","planned":false,"acquired":false,"shares":20221,"price":4.06,"value":82097.26,"ownership":{"direct":true},"balance_after":622980,"source":{"system":"sec-edgar","filing":"0000935836-25-000552","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000093583625000552/ownership.xml","form_type":"4"}},{"id":1121459,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2025-06-05T22:51:15.000Z","date":"2025-06-03","kind":"exercise","planned":false,"acquired":true,"shares":946460,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"These options vested monthly for 48 months following December 2, 2019."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Pursuant to a Transition Agreement with the Reporting Person, all unvested options were cancelled after June 30, 2024."}],"balance_after":0,"derivative":{"exercise_price":0.85,"expiration_date":"2029-12-02","underlying":"Common Stock","underlying_shares":946460},"source":{"system":"sec-edgar","filing":"0000935836-25-000416","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000093583625000416/ownership.xml","form_type":"4"}},{"id":1121458,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2025-06-05T22:51:15.000Z","date":"2025-06-03","kind":"exercise","planned":false,"acquired":true,"shares":131297,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These options vested monthly starting November 17, 2022, with cancellation of remaining options pursuant to Note 6 below."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Pursuant to a Transition Agreement with the Reporting Person, all unvested options were cancelled after June 30, 2024."}],"balance_after":0,"derivative":{"exercise_price":1.87,"expiration_date":"2032-11-17","underlying":"Common Stock","underlying_shares":131297},"source":{"system":"sec-edgar","filing":"0000935836-25-000416","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000093583625000416/ownership.xml","form_type":"4"}},{"id":1121457,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2025-06-05T22:51:15.000Z","date":"2025-06-03","kind":"exercise","planned":false,"acquired":true,"shares":105320,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options vested monthly starting March 17, 2023, with cancellation of remaining options pursuant to Note 6 below."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Pursuant to a Transition Agreement with the Reporting Person, all unvested options were cancelled after June 30, 2024."}],"balance_after":0,"derivative":{"exercise_price":0.481,"expiration_date":"2033-03-17","underlying":"Common Stock","underlying_shares":105320},"source":{"system":"sec-edgar","filing":"0000935836-25-000416","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000093583625000416/ownership.xml","form_type":"4"}},{"id":1121456,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2025-06-05T22:51:15.000Z","date":"2025-06-03","kind":"exercise","planned":false,"acquired":true,"shares":684528,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options vested monthly for 36 months following November 12, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Pursuant to a Transition Agreement with the Reporting Person, all unvested options were cancelled after June 30, 2024."}],"balance_after":0,"derivative":{"exercise_price":0.85,"expiration_date":"2029-12-02","underlying":"Common Stock","underlying_shares":684528},"source":{"system":"sec-edgar","filing":"0000935836-25-000416","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000093583625000416/ownership.xml","form_type":"4"}},{"id":1121455,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-05T22:51:15.000Z","date":"2025-06-03","kind":"sale","planned":false,"acquired":false,"shares":108532,"price":2.8703,"value":311519.3996,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents sale of Common Stock acquired from previously vested RSU awards."}],"balance_after":603501,"source":{"system":"sec-edgar","filing":"0000935836-25-000416","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000093583625000416/ownership.xml","form_type":"4"}},{"id":1121454,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-05T22:51:15.000Z","date":"2025-06-03","kind":"sale","planned":false,"acquired":false,"shares":1867605,"price":2.8703,"value":5360586.6315,"ownership":{"direct":true},"balance_after":712033,"source":{"system":"sec-edgar","filing":"0000935836-25-000416","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000093583625000416/ownership.xml","form_type":"4"}},{"id":1121453,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-05T22:51:15.000Z","date":"2025-06-03","kind":"exercise","planned":false,"acquired":true,"shares":946460,"price":0.85,"value":804491.0,"ownership":{"direct":true},"balance_after":2579638,"source":{"system":"sec-edgar","filing":"0000935836-25-000416","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000093583625000416/ownership.xml","form_type":"4"}},{"id":1121452,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-05T22:51:15.000Z","date":"2025-06-03","kind":"exercise","planned":false,"acquired":true,"shares":131297,"price":1.87,"value":245525.39,"ownership":{"direct":true},"balance_after":1633178,"source":{"system":"sec-edgar","filing":"0000935836-25-000416","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000093583625000416/ownership.xml","form_type":"4"}},{"id":1121451,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-05T22:51:15.000Z","date":"2025-06-03","kind":"exercise","planned":false,"acquired":true,"shares":105320,"price":0.481,"value":50658.92,"ownership":{"direct":true},"balance_after":1501881,"source":{"system":"sec-edgar","filing":"0000935836-25-000416","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000093583625000416/ownership.xml","form_type":"4"}},{"id":1121450,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-05T22:51:15.000Z","date":"2025-06-03","kind":"exercise","planned":false,"acquired":true,"shares":684528,"price":0.85,"value":581848.8,"ownership":{"direct":true},"balance_after":1396561,"source":{"system":"sec-edgar","filing":"0000935836-25-000416","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000093583625000416/ownership.xml","form_type":"4"}},{"id":1164915,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Warrant","published_at":"2025-04-28T23:20:14.000Z","date":"2025-03-26","kind":"purchase","planned":false,"acquired":true,"shares":22640,"price":0.125,"value":2830.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the \"Private Placement\"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued the reporting person Private Placement units consisting of two shares of the Company's common stock (\"Common Stock\") and a common warrant (\"Common Warrant\") to purchase one share of Common Stock (the \"Private Placement Unit\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the \"Private Placement\"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued the reporting person Private Placement units consisting of two shares of the Company's common stock (\"Common Stock\") and a common warrant (\"Common Warrant\") to purchase one share of Common Stock (the \"Private Placement Unit\")."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The issuance of the securities to the reporting person pursuant to the Private Placement was approved by the Company's board of directors and was deemed an exempt transaction pursuant to Rule 16b-3 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"This amendment is filed to correct the number of shares of Common Stock and number of Common Warrants acquired by the reporting person in the transaction reported on the original Form 4 filed on March 28, 2025. As a result of this correction, the amount of securities beneficially owned following the reported transaction specified in Table I, Column 5 and Table II, Column 9 have also been corrected."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each Private Placement Unit was purchased at a price of $2.2084 per unit, with a cost per share of Common Stock of $1.0417 and a cost per Common Warrant of $0.1250."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The reporting person may not exercise any portion of a Common Warrant to the extent that the reporting person would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately prior to or after giving effect to such exercise, as such percentage ownership is determined in accordance with Section 13(d) under the Exchange Act."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"This amendment is filed to correct the number of shares of Common Stock and number of Common Warrants acquired by the reporting person in the transaction reported on the original Form 4 filed on March 28, 2025. As a result of this correction, the amount of securities beneficially owned following the reported transaction specified in Table I, Column 5 and Table II, Column 9 have also been corrected."}],"balance_after":22640,"derivative":{"exercise_price":1.198,"exercise_date":"2025-03-26","expiration_date":"2030-03-26","underlying":"Common Stock","underlying_shares":22640},"source":{"system":"sec-edgar","filing":"0000935836-25-000296","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000093583625000296/ownership.xml","form_type":"4/A","original_submission_date":"2025-03-28"}},{"id":1164914,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-28T23:20:14.000Z","date":"2025-03-26","kind":"purchase","planned":false,"acquired":true,"shares":45280,"price":1.0417,"value":47168.176,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the \"Private Placement\"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued the reporting person Private Placement units consisting of two shares of the Company's common stock (\"Common Stock\") and a common warrant (\"Common Warrant\") to purchase one share of Common Stock (the \"Private Placement Unit\")."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The issuance of the securities to the reporting person pursuant to the Private Placement was approved by the Company's board of directors and was deemed an exempt transaction pursuant to Rule 16b-3 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"This amendment is filed to correct the number of shares of Common Stock and number of Common Warrants acquired by the reporting person in the transaction reported on the original Form 4 filed on March 28, 2025. As a result of this correction, the amount of securities beneficially owned following the reported transaction specified in Table I, Column 5 and Table II, Column 9 have also been corrected."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each Private Placement Unit was purchased at a price of $2.2084 per unit, with a cost per share of Common Stock of $1.0417 and a cost per Common Warrant of $0.1250."}],"balance_after":712033,"source":{"system":"sec-edgar","filing":"0000935836-25-000296","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000093583625000296/ownership.xml","form_type":"4/A","original_submission_date":"2025-03-28"}},{"id":1188872,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Warrant","published_at":"2025-03-28T21:34:59.000Z","date":"2025-03-26","kind":"purchase","planned":false,"acquired":true,"shares":4528,"price":0.125,"value":566.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the \"Private Placement\"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued the reporting person Private Placement units consisting of two shares of the Company's common stock (\"Common Stock\") and a common warrant (\"Common Warrant\") to purchase one share of Common Stock (the \"Private Placement Unit\")."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the \"Private Placement\"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued the reporting person Private Placement units consisting of two shares of the Company's common stock (\"Common Stock\") and a common warrant (\"Common Warrant\") to purchase one share of Common Stock (the \"Private Placement Unit\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The issuance of the securities to the reporting person pursuant to the Private Placement was approved by the Company's board of directors and was deemed an exempt transaction pursuant to Rule 16b-3 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each Private Placement Unit was purchased at a price of $2.2084 per unit, with a cost per share of Common Stock of $1.0417 and a cost per Common Warrant of $0.1250."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The reporting person may not exercise any portion of a Common Warrant to the extent that the reporting person would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately prior to or after giving effect to such exercise, as such percentage ownership is determined in accordance with Section 13(d) under the Exchange Act."}],"balance_after":4528,"derivative":{"exercise_price":1.198,"exercise_date":"2025-03-26","expiration_date":"2030-03-26","underlying":"Common Stock","underlying_shares":4528},"source":{"system":"sec-edgar","filing":"0001079973-25-000521","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000107997325000521/ownership.xml","form_type":"4"}},{"id":1188871,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-28T21:34:59.000Z","date":"2025-03-26","kind":"purchase","planned":false,"acquired":true,"shares":9056,"price":1.0417,"value":9433.6352,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the \"Private Placement\"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued the reporting person Private Placement units consisting of two shares of the Company's common stock (\"Common Stock\") and a common warrant (\"Common Warrant\") to purchase one share of Common Stock (the \"Private Placement Unit\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The issuance of the securities to the reporting person pursuant to the Private Placement was approved by the Company's board of directors and was deemed an exempt transaction pursuant to Rule 16b-3 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each Private Placement Unit was purchased at a price of $2.2084 per unit, with a cost per share of Common Stock of $1.0417 and a cost per Common Warrant of $0.1250."}],"balance_after":675809,"source":{"system":"sec-edgar","filing":"0001079973-25-000521","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000107997325000521/ownership.xml","form_type":"4"}},{"id":1347271,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2024-12-02T21:04:53.000Z","date":"2024-12-02","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":0.15,"value":7500.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"44,000 being restricted stock units that vest in full on the date of the Company's 2025 annual meeting of stockholders, subject to continued service with the Company through such vesting date."}],"balance_after":666753,"source":{"system":"sec-edgar","filing":"0001799191-24-000063","document":"wk-form4_1733173486.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000179919124000063/wk-form4_1733173486.xml","form_type":"4"}},{"id":1347270,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2024-12-02T21:04:53.000Z","date":"2024-11-26","kind":"purchase","planned":false,"acquired":true,"shares":250000,"price":0.17,"value":42500.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"44,000 being restricted stock units that vest in full on the date of the Company's 2025 annual meeting of stockholders, subject to continued service with the Company through such vesting date."}],"balance_after":616753,"source":{"system":"sec-edgar","filing":"0001799191-24-000063","document":"wk-form4_1733173486.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000179919124000063/wk-form4_1733173486.xml","form_type":"4"}},{"id":1347269,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2024-12-02T21:04:53.000Z","date":"2024-11-12","kind":"other","planned":false,"acquired":false,"shares":353450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects the forfeiture of restricted earn-out shares that were unvested due to failure to meet earnout targets of the Issuer's stock price of $12.50 and $15.00 per share for 20 days within any 30 consecutive trading days for the three-year period following November 12, 2021, the date of the closing of the Business Combination, subject to continued employment at such time."}],"balance_after":366753,"source":{"system":"sec-edgar","filing":"0001799191-24-000063","document":"wk-form4_1733173486.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000179919124000063/wk-form4_1733173486.xml","form_type":"4"}},{"id":1352800,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2024-11-25T21:14:48.000Z","date":"2024-11-22","kind":"grant","planned":false,"acquired":true,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest in full on TOI, Inc.'s 2025 annual shareholder meeting date, subject to continued service with the Company through such vesting date."}],"balance_after":720203,"source":{"system":"sec-edgar","filing":"0001799191-24-000050","document":"wk-form4_1732569282.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000179919124000050/wk-form4_1732569282.xml","form_type":"4"}},{"id":1473274,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-20T20:17:38.000Z","date":"2024-06-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18121,"price":0.4578,"value":8295.7938,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs) pursuant to a sell-to-cover provision included in the RSU Agreement."}],"balance_after":676203,"source":{"system":"sec-edgar","filing":"0001799191-24-000015","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000179919124000015/edgardoc.xml","form_type":"4"}},{"id":1503774,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-23T23:22:21.000Z","date":"2024-05-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":19526,"price":0.5753,"value":11233.3078,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs) pursuant to a sell-to-cover provision included in the RSU Agreement."}],"balance_after":694324,"source":{"system":"sec-edgar","filing":"0001799191-24-000013","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000179919124000013/edgardoc.xml","form_type":"4"}},{"id":1698739,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2023-12-28T22:46:15.000Z","date":"2023-12-26","kind":"grant","planned":false,"acquired":true,"shares":42652,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted stock units that vest in full on TOI, Inc. 2024 annual shareholder meeting date, subject to continued service with the Company through such vesting date."}],"balance_after":713850,"source":{"system":"sec-edgar","filing":"0001628280-23-042829","document":"wk-form4_1703803565.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000162828023042829/wk-form4_1703803565.xml","form_type":"4"}},{"id":1731363,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2023-11-23T02:01:30.000Z","date":"2023-11-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25867,"price":2.193,"value":56726.331,"ownership":{"direct":true},"balance_after":671198,"source":{"system":"sec-edgar","filing":"0001628280-23-039913","document":"wk-form4_1700704878.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000162828023039913/wk-form4_1700704878.xml","form_type":"4"}},{"id":1732813,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-11-22T00:27:35.000Z","date":"2023-11-17","kind":"exercise","planned":false,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest monthly for 36 months following November 12, 2021, the date of the closing of the Business Combination."}],"balance_after":1745431,"derivative":{"exercise_price":0.85,"expiration_date":"2029-12-02","underlying":"Common stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001628280-23-039815","document":"wk-form4_1700612843.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000162828023039815/wk-form4_1700612843.xml","form_type":"4"}},{"id":1732812,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2023-11-22T00:27:35.000Z","date":"2023-11-17","kind":"sale","planned":false,"acquired":false,"shares":25000,"price":2.24,"value":56000.0,"ownership":{"direct":true},"balance_after":697065,"source":{"system":"sec-edgar","filing":"0001628280-23-039815","document":"wk-form4_1700612843.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000162828023039815/wk-form4_1700612843.xml","form_type":"4"}},{"id":1732811,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2023-11-22T00:27:35.000Z","date":"2023-11-17","kind":"exercise","planned":false,"acquired":true,"shares":25000,"price":0.85,"value":21250.0,"ownership":{"direct":true},"balance_after":722065,"source":{"system":"sec-edgar","filing":"0001628280-23-039815","document":"wk-form4_1700612843.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000162828023039815/wk-form4_1700612843.xml","form_type":"4"}},{"id":1740900,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-11-15T23:49:28.000Z","date":"2023-11-13","kind":"exercise","planned":false,"acquired":false,"shares":47000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest as to 1/4th of the total number of shares subject to the option on the first anniversary of December 2, 2019 (the \"Original Grant Date\"), and as to 1/36th of the total number of shares monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Original Grant Date, subject to continued employment through the vest date."}],"balance_after":1770431,"derivative":{"exercise_price":0.85,"expiration_date":"2029-12-02","underlying":"Common stock","underlying_shares":47000},"source":{"system":"sec-edgar","filing":"0001628280-23-039192","document":"wk-form4_1700092157.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000162828023039192/wk-form4_1700092157.xml","form_type":"4"}},{"id":1740899,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2023-11-15T23:49:28.000Z","date":"2023-11-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":27117,"price":2.388,"value":64755.396,"ownership":{"direct":true},"balance_after":697065,"source":{"system":"sec-edgar","filing":"0001628280-23-039192","document":"wk-form4_1700092157.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000162828023039192/wk-form4_1700092157.xml","form_type":"4"}},{"id":1740898,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2023-11-15T23:49:28.000Z","date":"2023-11-13","kind":"sale","planned":false,"acquired":false,"shares":47000,"price":2.523,"value":118581.0,"ownership":{"direct":true},"balance_after":724182,"source":{"system":"sec-edgar","filing":"0001628280-23-039192","document":"wk-form4_1700092157.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000162828023039192/wk-form4_1700092157.xml","form_type":"4"}},{"id":1740897,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2023-11-15T23:49:28.000Z","date":"2023-11-13","kind":"exercise","planned":false,"acquired":true,"shares":47000,"price":0.85,"value":39950.0,"ownership":{"direct":true},"balance_after":771182,"source":{"system":"sec-edgar","filing":"0001628280-23-039192","document":"wk-form4_1700092157.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000162828023039192/wk-form4_1700092157.xml","form_type":"4"}},{"id":1943157,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-03-22T00:44:26.000Z","date":"2023-03-17","kind":"grant","planned":false,"acquired":true,"shares":421280,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options vest as to 1/4th of the options granted on the first anniversary of the Vesting Commencement Date, with the remaining options vesting in four equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all options becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates."}],"balance_after":421280,"derivative":{"exercise_price":0.481,"expiration_date":"2033-03-17","underlying":"Common stock","underlying_shares":421280},"source":{"system":"sec-edgar","filing":"0001628280-23-008825","document":"wf-form4_167944585635107.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000162828023008825/wf-form4_167944585635107.xml","form_type":"4"}},{"id":1943156,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2023-03-22T00:44:26.000Z","date":"2023-03-17","kind":"grant","planned":false,"acquired":true,"shares":168512,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents RSUs with 1/4th of the RSUs vesting on the anniversary of March 17, 2023 (the Vesting Commencement Date), with the remaining RSUs vesting in three equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all RSUs becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents RSUs with 1/4th of the RSUs vesting on the anniversary of March 17, 2023 (the Vesting Commencement Date), with the remaining RSUs vesting in three equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all RSUs becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates."}],"balance_after":724182,"source":{"system":"sec-edgar","filing":"0001628280-23-008825","document":"wf-form4_167944585635107.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000162828023008825/wf-form4_167944585635107.xml","form_type":"4"}},{"id":2107025,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-11-23T01:07:22.000Z","date":"2022-11-15","kind":"sale","acquired":false,"shares":9718,"price":2.0278,"value":19706.1604,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4/A amends and restates the reporting persons Form 4 originally filed on November 17, 2022 in the entirety. This Form 4/A is being filed to correct the reporting persons original Form 4 from Code D to Code S. The sales reported in the Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs) pursuant to a sell-to-cover provision included in the RSU Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Price is the volume weighted average selling price of all sales by the Reporting Person on November 15, 2022 within a one-dollar range. Actual prices ranged from $2.025 to $2.028. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price."}],"balance_after":452201,"source":{"system":"sec-edgar","filing":"0001799191-22-000050","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000179919122000050/edgardoc.xml","form_type":"4/A","original_submission_date":"2022-11-17"}},{"id":2108722,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-11-21T22:31:48.000Z","date":"2022-11-17","kind":"grant","acquired":true,"shares":525188,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options vest as to 1/4th of the options granted on the first anniversary of the Vesting Commencement Date, with the remaining options vesting in four equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all options becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates."}],"balance_after":525188,"derivative":{"exercise_price":1.87,"expiration_date":"2032-11-17","underlying":"Common Stock","underlying_shares":525188},"source":{"system":"sec-edgar","filing":"0001799191-22-000032","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000179919122000032/edgardoc.xml","form_type":"4"}},{"id":2108721,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-11-21T22:31:48.000Z","date":"2022-11-17","kind":"grant","acquired":true,"shares":103469,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents RSUs with 1/4th of the RSUs vesting on the anniversary of November 17, 2022 (the Vesting Commencement Date), with the remaining RSUs vesting in three equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all RSUs becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates."}],"balance_after":555670,"source":{"system":"sec-edgar","filing":"0001799191-22-000032","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000179919122000032/edgardoc.xml","form_type":"4"}},{"id":2112324,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-11-17T22:30:26.000Z","date":"2022-11-15","kind":"disposition_to_issuer","acquired":false,"shares":9718,"price":2.0278,"value":19706.1604,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs) pursuant to a sell-to-cover provision included in the RSU Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Price is the volume weighted average selling price of all sales by the Reporting Person on November 15, 2022 within a one-dollar range. Actual prices ranged from $2.025 to $2.028. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price."}],"balance_after":452201,"source":{"system":"sec-edgar","filing":"0001799191-22-000012","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000179919122000012/edgardoc.xml","form_type":"4"}},{"id":2315410,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-30T00:10:26.000Z","date":"2022-03-21","kind":"grant","acquired":true,"shares":550563,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest in four equal annual installments on each of the first four anniversaries of November 12, 2021 (the \"Vesting Commencement Date\"), with all options becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates."}],"balance_after":550563,"derivative":{"exercise_price":7.09,"expiration_date":"2032-03-21","underlying":"Common stock","underlying_shares":550563},"source":{"system":"sec-edgar","filing":"0001628280-22-007759","document":"wf-form4a_164859901030434.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000162828022007759/wf-form4a_164859901030434.xml","form_type":"4/A","original_submission_date":"2022-03-23"}},{"id":2320136,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-23T23:36:54.000Z","date":"2022-03-21","kind":"grant","acquired":true,"shares":88090,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options vest in four equal annual installments on each of the first four anniversaries of the Vesting Commencement Date, with all options becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates."}],"balance_after":88090,"derivative":{"exercise_price":7.09,"expiration_date":"2032-03-21","underlying":"Common stock","underlying_shares":88090},"source":{"system":"sec-edgar","filing":"0001628280-22-007101","document":"wf-form4_164807859777265.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000162828022007101/wf-form4_164807859777265.xml","form_type":"4"}},{"id":2320135,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2022-03-23T23:36:54.000Z","date":"2022-03-21","kind":"grant","acquired":true,"shares":108469,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") that vest in four equal annual installments on each of the first four anniversaries of November 12, 2021 (the \"Vesting Commencement Date\"), with all RSUs becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted stock units (\"RSUs\") that vest in four equal annual installments on each of the first four anniversaries of November 12, 2021 (the \"Vesting Commencement Date\"), with all RSUs becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The reporting person's last filing incorrectly reported 363,450 total holdings instead of 353,450 total holdings."}],"balance_after":461919,"source":{"system":"sec-edgar","filing":"0001628280-22-007101","document":"wf-form4_164807859777265.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000162828022007101/wf-form4_164807859777265.xml","form_type":"4"}},{"id":2505016,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-11-19T01:25:53.000Z","date":"2021-11-12","kind":"grant","acquired":true,"shares":212070,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares were received in connection with the Business Combination and represent restricted earn-out shares subject to forfeiture and unvested until such time the Issuer's stock price reaches $12.50 per share for 20 days within any 30 consecutive trading days for the two-year period following the closing of the Business Combination, subject to continued employment at such time."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"On November 12, 2021, pursuant to that certain Agreement and Plan of Merger (\"Merger Agreement\"), dated as June 28, 2021, by and among DFP Healthcare Acquisitions Corp. (\"DFP\"), Orion Merger Sub I, Inc. (\"First Merger Sub\"), Orion Merger Sub II, LLC (\"Second Merger Sub\"), and TOI Parent, Inc. (\"Old TOI\"), First Merger Sub merged into Old TOI, with Old TOI being the surviving corporation then Old TOI merged into Second Merger Sub, with Second Merger Sub being the surviving entity and a wholly owned subsidiary of DFP, which then changed its name to The Oncology Institute, Inc. (such transactions, collectively, the \"Business Combination\"). Upon consummation of the Business Combination, each issued and outstanding share of common stock of Old TOI was automatically cancelled and the holder thereof was entitled to receive its allocable share of cash and stock consideration pursuant to the Merger Agreement."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F3","text":"The shares were received in connection with the Business Combination and represent restricted earn-out shares subject to forfeiture and unvested until such time the Issuer's stock price reaches $15.00 per share for 20 days within any 30 consecutive trading days for the three-year period following the closing of the Business Combination, subject to continued employment at such time."}],"balance_after":363450,"source":{"system":"sec-edgar","filing":"0001104659-21-141460","document":"tm2133425-3_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000110465921141460/tm2133425-3_4aseq1.xml","form_type":"4/A","original_submission_date":"2021-11-16"}},{"id":2505015,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-11-19T01:25:53.000Z","date":"2021-11-12","kind":"grant","acquired":true,"shares":141380,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares were received in connection with the Business Combination and represent restricted earn-out shares subject to forfeiture and unvested until such time the Issuer's stock price reaches $12.50 per share for 20 days within any 30 consecutive trading days for the two-year period following the closing of the Business Combination, subject to continued employment at such time."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"On November 12, 2021, pursuant to that certain Agreement and Plan of Merger (\"Merger Agreement\"), dated as June 28, 2021, by and among DFP Healthcare Acquisitions Corp. (\"DFP\"), Orion Merger Sub I, Inc. (\"First Merger Sub\"), Orion Merger Sub II, LLC (\"Second Merger Sub\"), and TOI Parent, Inc. (\"Old TOI\"), First Merger Sub merged into Old TOI, with Old TOI being the surviving corporation then Old TOI merged into Second Merger Sub, with Second Merger Sub being the surviving entity and a wholly owned subsidiary of DFP, which then changed its name to The Oncology Institute, Inc. (such transactions, collectively, the \"Business Combination\"). Upon consummation of the Business Combination, each issued and outstanding share of common stock of Old TOI was automatically cancelled and the holder thereof was entitled to receive its allocable share of cash and stock consideration pursuant to the Merger Agreement."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"These shares were received in connection with the Business Combination and represent restricted earn-out shares subject to forfeiture and unvested until such time the Issuer's stock price reaches $12.50 per share for 20 days within any 30 consecutive trading days for the two-year period following the closing of the Business Combination, subject to continued employment at such time."}],"balance_after":141380,"source":{"system":"sec-edgar","filing":"0001104659-21-141460","document":"tm2133425-3_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000110465921141460/tm2133425-3_4aseq1.xml","form_type":"4/A","original_submission_date":"2021-11-16"}},{"id":2510839,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (right to buy)","published_at":"2021-11-17T02:53:41.000Z","date":"2021-11-12","kind":"grant","acquired":true,"shares":823971,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"These stock options were received in connection with the Business Combination in exchange for performance based stock options to acquire shares of Old TOI, and reflect the holder's allocable share of stock consideration pursuant to the Merger Agreement. These options vest monthly for 36 months following November 12, 2021, the date of the closing of the Business Combination, subject to continued employment through the vest date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"These stock options were received in connection with the Business Combination in exchange for performance based stock options to acquire shares of Old TOI, and reflect the holder's allocable share of stock consideration pursuant to the Merger Agreement. These options vest monthly for 36 months following November 12, 2021, the date of the closing of the Business Combination, subject to continued employment through the vest date."}],"derivative":{"exercise_price":0.85,"expiration_date":"2029-12-02","underlying":"Common Stock","underlying_shares":823971},"source":{"system":"sec-edgar","filing":"0001104659-21-140219","document":"tm2132979-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000110465921140219/tm2132979-10_4seq1.xml","form_type":"4"}},{"id":2510838,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (right to buy)","published_at":"2021-11-17T02:53:41.000Z","date":"2021-11-12","kind":"grant","acquired":true,"shares":993460,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"These stock options were received in connection with the Business Combination in exchange for time-vested stock options to acquire shares of Old TOI, and reflect the holder's allocable share of stock consideration pursuant to the Merger Agreement. These options vest as to 1/4th of the total number of shares subject to the option on the first anniversary of November 16, 2020 (the \"Original Grant Date\"), and as 1/36th of the total number of shares monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Original Grant Date, subject to continued employment through the vest date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These stock options were received in connection with the Business Combination in exchange for time-vested stock options to acquire shares of Old TOI, and reflect the holder's allocable share of stock consideration pursuant to the Merger Agreement. These options vest as to 1/4th of the total number of shares subject to the option on the first anniversary of November 16, 2020 (the \"Original Grant Date\"), and as 1/36th of the total number of shares monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Original Grant Date, subject to continued employment through the vest date."}],"derivative":{"exercise_price":0.85,"expiration_date":"2029-12-02","underlying":"Common Stock","underlying_shares":993460},"source":{"system":"sec-edgar","filing":"0001104659-21-140219","document":"tm2132979-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000110465921140219/tm2132979-10_4seq1.xml","form_type":"4"}},{"id":2510837,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-11-17T02:53:41.000Z","date":"2021-01-12","kind":"grant","acquired":true,"shares":212070,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares were received in connection with the Business Combination and represent restricted earn-out shares subject to forfeiture and unvested until such time the Issuer's stock price reaches $12.50 per share for 20 days within any 30 consecutive trading days for the two-year period following the closing of the Business Combination, subject to continued employment at such time."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"On November 12, 2021, pursuant to that certain Agreement and Plan of Merger (\"Merger Agreement\"), dated as June 28, 2021, by and among  DFP Healthcare Acqusitions Corp. (\"DFP\"), Orion Merger Sub I, Inc. (\"First Merger Sub\"), Orion Merger Sub II, LLC (\"Second Merger Sub\"), and TOI Parent, Inc. (\"Old TOI\"), First Merger Sub merged into Old TOI, with Old TOI being the surivivng corporation then Old TOI merged into Second Merger Sub, with Second Merger Sub being the surviving entity and a wholly owned subsidiary of DFP, which then changed its name to The Oncology Institute, Inc. (such transactions, collectively, the \"Business Combination\"). Upon consummation of the Business Combination, each issued and outstanding share of common stock of Old TOI was automatically cancelled and the holder thereof was entitled to receive its allocable share of cash and stock consideration pursuant to the Merger Agreement."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F3","text":"The shares were received in connection with the Business Combination and represent restricted earn-out shares subject to forfeiture and unvested until such time the Issuer's stock price reaches $15.00 per share for 20 days within any 30 consecutive trading days for the three-year period following the closing of the Business Combination, subject to continued employment at such time."}],"balance_after":212070,"source":{"system":"sec-edgar","filing":"0001104659-21-140219","document":"tm2132979-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000110465921140219/tm2132979-10_4seq1.xml","form_type":"4"}},{"id":2510836,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":20372,"kind":"person","name":"Hively Brad","position":1,"cik":"0001891124","reported_name":"Hively Brad","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-11-17T02:53:41.000Z","date":"2021-01-12","kind":"grant","acquired":true,"shares":141380,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares were received in connection with the Business Combination and represent restricted earn-out shares subject to forfeiture and unvested until such time the Issuer's stock price reaches $12.50 per share for 20 days within any 30 consecutive trading days for the two-year period following the closing of the Business Combination, subject to continued employment at such time."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"On November 12, 2021, pursuant to that certain Agreement and Plan of Merger (\"Merger Agreement\"), dated as June 28, 2021, by and among  DFP Healthcare Acqusitions Corp. (\"DFP\"), Orion Merger Sub I, Inc. (\"First Merger Sub\"), Orion Merger Sub II, LLC (\"Second Merger Sub\"), and TOI Parent, Inc. (\"Old TOI\"), First Merger Sub merged into Old TOI, with Old TOI being the surivivng corporation then Old TOI merged into Second Merger Sub, with Second Merger Sub being the surviving entity and a wholly owned subsidiary of DFP, which then changed its name to The Oncology Institute, Inc. (such transactions, collectively, the \"Business Combination\"). Upon consummation of the Business Combination, each issued and outstanding share of common stock of Old TOI was automatically cancelled and the holder thereof was entitled to receive its allocable share of cash and stock consideration pursuant to the Merger Agreement."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"These shares were received in connection with the Business Combination and represent restricted earn-out shares subject to forfeiture and unvested until such time the Issuer's stock price reaches $12.50 per share for 20 days within any 30 consecutive trading days for the two-year period following the closing of the Business Combination, subject to continued employment at such time."}],"balance_after":141380,"source":{"system":"sec-edgar","filing":"0001104659-21-140219","document":"tm2132979-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000110465921140219/tm2132979-10_4seq1.xml","form_type":"4"}}]}